Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Study:

Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion In Patients With Metastatic, Locally Advanced, or Unresectable Renal Cell Carcinoma

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Kidney Cancer Drug: DHA-paclitaxel Phase 2

Verified by Theradex June, 2002

Sponsored by: Theradex
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00024388

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Ronald M. Bukowski, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site